New Batch Of Psilocybin Microdose Capsules Is Ready, Learn All The Details
New Batch Of Psilocybin Microdose Capsules Is Ready, Learn All The Details
Canadian-based psychedelics company Nova Mentis Life Science Corp. (OTCQB:NMLSF), or NOVA, is collaborating with the Toronto Institute of Pharmaceutical Technology (TIPT), a Health Canada-licensed GMP manufacturing and testing facility, to complete the production of an engineering quantity of psilocybin microdose capsules.
The partners are moving forward with the release testing stage in order to generate data required by Canada's application process towards advancing a Phase IIa clinical trial on psilocybin microdose therapy for Fragile X Syndrome (FXS), the leading genetic cause of Autism Spectrum Disorder (ASD).
The company has partnered with contract research organization KGK Science Inc. to develop its psilocybin drug portfolio by jointly submitting the Health Canada clinical trial application.
NOVA's work focuses on developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders and debilitating chronic conditions.
The company achieved orphan drug designation in both the US and the European Union for the use of psilocybin for the treatment of FXS. Following drug approval, NOVA has manufactured a large supply of >98% pure psilocybin for clinical studies and commercialization.
Recent preclinical research showed that a very low microdose formulation of NOVA's psilocybin compound NM-1001 significantly modulated behavioral and cognitive defects in a genetic model of FXS.
Photo by Robina Weermeijer on Unsplash
Canadian-based psychedelics company Nova Mentis Life Science Corp. (OTCQB:NMLSF), or NOVA, is collaborating with the Toronto Institute of Pharmaceutical Technology (TIPT), a Health Canada-licensed GMP manufacturing and testing facility, to complete the production of an engineering quantity of psilocybin microdose capsules.
加拿大迷幻药公司Nova Mentis生命科学公司(OTCQB：NMLSF)，或Nova，正在与多伦多制药技术研究所(TIP)，加拿大卫生部许可的GMP制造和测试设施，以完成工程量裸盖菇素微剂量胶囊的生产。
The partners are moving forward with the release testing stage in order to generate data required by Canada's application process towards advancing a Phase IIa clinical trial on psilocybin microdose therapy for Fragile X Syndrome (FXS), the leading genetic cause of Autism Spectrum Disorder (ASD).
合作伙伴正在推进版本测试阶段，以便生成加拿大应用程序所需的数据，以实现推进裸盖菇素微剂量治疗脆性X综合征的IIa期临床试验，自闭症谱系障碍(ASD)的主要遗传原因。
The company has partnered with contract research organization KGK Science Inc. to develop its psilocybin drug portfolio by jointly submitting the Health Canada clinical trial application.
该公司已经与合同研究机构KGK科学公司合作，通过联合提交加拿大卫生部的临床试验申请来开发其裸盖菇素药物组合。
NOVA's work focuses on developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders and debilitating chronic conditions.
Nova的工作重点是开发诊断和基于裸盖菇素的疗法，用于治疗神经炎性疾病和使人虚弱的慢性疾病。
The company achieved orphan drug designation in both the US and the European Union for the use of psilocybin for the treatment of FXS. Following drug approval, NOVA has manufactured a large supply of >98% pure psilocybin for clinical studies and commercialization.
该公司在美国和欧盟都获得了使用裸盖菇素治疗FXS的孤儿药物指定。在药物批准后，Nova生产了大量的>98%的裸盖菇素用于临床研究和商业化。
Recent preclinical research showed that a very low microdose formulation of NOVA's psilocybin compound NM-1001 significantly modulated behavioral and cognitive defects in a genetic model of FXS.
最近的临床前研究表明，Nova公司的裸盖菇素化合物的极低剂量配方NM-1001在FXS的遗传模型中，显著调节了行为和认知缺陷。
Photo by Robina Weermeijer on Unsplash
Robina Weermeijer在Unspash上的照片
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧